Monoamine Oxidase Inhibitors
"Monoamine Oxidase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
| Descriptor ID |
D008996
|
| MeSH Number(s) |
D27.505.519.389.616
|
| Concept/Terms |
Monoamine Oxidase Inhibitors- Monoamine Oxidase Inhibitors
- Inhibitors, Monoamine Oxidase
- Monoamine Oxidase Inhibitor
- Inhibitor, Monoamine Oxidase
- MAO Inhibitors
- Inhibitors, MAO
|
Below are MeSH descriptors whose meaning is more general than "Monoamine Oxidase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Monoamine Oxidase Inhibitors".
This graph shows the total number of publications written about "Monoamine Oxidase Inhibitors" by people in this website by year, and whether "Monoamine Oxidase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Monoamine Oxidase Inhibitors" by people in Profiles.
-
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
-
Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1. PLoS One. 2017; 12(2):e0170301.
-
A female case of aromatic l-amino acid decarboxylase deficiency responsive to MAO-B inhibition. Brain Dev. 2016 Nov; 38(10):959-963.
-
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016 Mar 12; 9:24.
-
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. J Med Chem. 2016 Jan 14; 59(1):253-263.
-
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis. 2013 Jun; 34(6):1196-207.
-
Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol. 2011 Aug; 13(8):894-903.
-
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
-
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006 Jun; 13(6):563-7.
-
Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May; 11(5):363-75.